Orforglipron
- Generic Name
- Orforglipron
A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy Participants
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2022-11-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 26
- Registration Number
- NCT05469126
- Locations
- 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore
A Study of Two Different Formulations of LY3502970 in Healthy Participants
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 39
- Registration Number
- NCT05341089
- Locations
- 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore
A Study of LY3502970 in Healthy Overweight and Obese Participants
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 72
- Registration Number
- NCT05313802
- Locations
- 🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States
🇺🇸Qps-Mra, Llc, Miami, Florida, United States
🇺🇸ICON Early Phase Services Lenexa Center, Lenexa, Kansas, United States
A Multiple-Dose Study of LY3502970 in Healthy Participants
- First Posted Date
- 2021-11-08
- Last Posted Date
- 2022-06-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 33
- Registration Number
- NCT05110794
- Locations
- 🇸🇬
Lilly Centre for Clinical Pharmacology, Singapore, Singapore
A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus
- First Posted Date
- 2021-10-21
- Last Posted Date
- 2022-11-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 62
- Registration Number
- NCT05086445
- Locations
- 🇯🇵
Medical Corporation Heishinkai OPHAC Hospital, Osaka-shi, Osaka, Japan
🇯🇵Clinical Research Hospital Tokyo, Shinjuku-ku, Tokyo, Japan
🇯🇵P-One Clinic, Hachioji, Tokyo, Japan
A Multiple Dose Study of LY3502970 in Healthy Participants
- First Posted Date
- 2021-09-21
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 26
- Registration Number
- NCT05051566
- Locations
- 🇬🇧
Quotient Clinical Ltd, Nottingham, United Kingdom
A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities
- First Posted Date
- 2021-09-21
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 272
- Registration Number
- NCT05051579
- Locations
- 🇭🇺
DRC Gyógyszervizsgáló Központ, Balatonfüred, Veszprém, Hungary
🇺🇸Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸Valley Clinical Trials, Inc., Northridge, California, United States
A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 383
- Registration Number
- NCT05048719
- Locations
- 🇸🇰
MEDI-DIA s.r.o., Sabinov, Prešovský Kraj, Slovakia
🇸🇰Funkystuff, Nove Zamky, Slovakia
🇺🇸Cotton O'Neil Clinical Research Center, Topeka, Kansas, United States
A Study of LY3502970 in Healthy Male Participants
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2021-07-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 6
- Registration Number
- NCT04680767
- Locations
- 🇬🇧
Covance Clinical Research, Leeds, United Kingdom
A Study of LY3502970 in Participants With Type 2 Diabetes
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2021-07-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 68
- Registration Number
- NCT04426474
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung, Neuss, Nordrhein-Westfalen, Germany
🇺🇸Endeavor Clinical Trials, San Antonio, Texas, United States
🇺🇸Hassman Research Institute, Marlton, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.